<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02134899</url>
  </required_header>
  <id_info>
    <org_study_id>P 090804</org_study_id>
    <secondary_id>2012-004265-41</secondary_id>
    <nct_id>NCT02134899</nct_id>
  </id_info>
  <brief_title>The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients</brief_title>
  <acronym>EVERKYSTE</acronym>
  <official_title>An Open-labelled Multicenter Randomized Study on the Efficacy of Everolimus in Reducing Total Native Kidney Volume in Kidney Transplanted Patients With Autosomal Dominant Polycystic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators multicenter randomized open-labelled study will investigate the efficacy of
      an everolimus based immunosuppression in reducing total native kidney volume in kidney
      recipients with autosomal dominant polycystic kidney disease compared to a calcineurin
      inhibitor-based immunosuppression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Kidney graft recipients receiving a firs kidney graft (between 6 months and 5 years
      post-transplantation) will be randomized 1:1 to receive an everolimus based immunosuppression
      (in association with steroids and mycophenolate mofetil) or to continue their calcineurin
      inhibitor-based immunosuppression regimen. The primary objective will be the reduction of
      total native kidney volume after a 2-years treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total native kidney volume variation</measure>
    <time_frame>24 months after randomization</time_frame>
    <description>measurements of total native kidney volume with a MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Volume variation of the biggest liver cyst</measure>
    <time_frame>24 months after randomization</time_frame>
    <description>Measurements of the biggest liver cyst volume with a MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interstitial Fibrosis/Tubular Atrophy variation</measure>
    <time_frame>24 months after randomization</time_frame>
    <description>IF/TA quantification using Banff criteria during a kidney biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% interstitial fibrosis using Red Sirius staining</measure>
    <time_frame>24 months after randomization</time_frame>
    <description>% fibrosis quantified using a morphometry software</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calculated Estimated Glomerular Filtration rate</measure>
    <time_frame>At baseline, 1 month, 6 months, 12 months, 18 and 24 months</time_frame>
    <description>calculated estimated GFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measured Glomerular Filtration rate</measure>
    <time_frame>At baseline and 24 months</time_frame>
    <description>measured GFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proteinuria</measure>
    <time_frame>At baseline, 1 month, 6 months, 12 months, 18 and 24 months</time_frame>
    <description>Measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systolic and diastolic blood pressure</measure>
    <time_frame>At baseline, 1 month, 6 months, 12 months, 18 and 24 months</time_frame>
    <description>Clinic measurement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of diabetes or hyperlipidemia</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of neoplasia</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Medical chart reporting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of HLA Donor Specific Antibody (DSA)</measure>
    <time_frame>At baseline, 1 month, 6 months, 12 months, 18 and 24 months</time_frame>
    <description>V0, 1 year and 2 years after randomization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>everolimus based immunosuppression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcineurin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcineurin inhibitors maintenance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Change from a calcineurin inhibitors-based immunosuppression to an everolimus-based immunosuppression</description>
    <arm_group_label>Everolimus</arm_group_label>
    <other_name>everolimus conversion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcineurin inhibitors maintenance</intervention_name>
    <description>Usual treatment</description>
    <arm_group_label>Calcineurin</arm_group_label>
    <other_name>calcineurin-inhibitors based immunosuppression</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 18 and 75 years-old

          -  recipients of a first kidney graft between 6 month and 5 years ago with a stable eGFR
             above 30 ml/min/1,73m2

          -  contraception for female recipients to avoid pregnancy

          -  valid health Insurance during the study period

        Exclusion Criteria:

          -  signed informed consent not obtained
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène François, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hélène François, MD, PhD</last_name>
    <phone>+33(1)45 21 27 22</phone>
    <email>helene.francois@bct.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Bicêtre Hospital</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène François</last_name>
      <phone>+33(1)45 21 27 22</phone>
      <email>helene.francois@bct.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Hélène François, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2014</study_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autosomal dominant polycystic kidney disease</keyword>
  <keyword>cyst</keyword>
  <keyword>kidney</keyword>
  <keyword>liver</keyword>
  <keyword>kidney transplantation</keyword>
  <keyword>IF/TA</keyword>
  <keyword>fibrosis</keyword>
  <keyword>DSA</keyword>
  <keyword>mTOR inhibitors</keyword>
  <keyword>calcineurin inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

